GlobeNewswire - News from Massachusetts

Imara to Webcast Conference Call of Full Year 2020 Financial Results and Business Highlights

2021-02-27T02:30:00Z

BOSTON, Feb. 26, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, today announced that the company will host a conference call and live webcast on Friday, March 5, 2021 at 8:30 a.m. ET to discuss its financial results for the year ended December 31, 2020 and review recent business highlights.

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

2021-02-27T00:12:46Z

CAMBRIDGE, Mass., Feb. 26, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on Feb. 26, 2021 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta��s 2014 Employment Commencement Incentive Plan, as a material inducement to employment to 2 individuals hired by Sarepta in February 2021. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).

CPS Technologies Corporation Conference Call Replay

2021-02-26T21:10:02Z

NORTON, Mass., Feb. 26, 2021 (GLOBE NEWSWIRE) -- CPS Technologies Corporation (NASDAQ:CPSH) has posted the recording of its February 24, 2021 Investor Call on its website. A brief summary of the call including the minute and second mark in which specific topics are discussed appears below.

ReWalk Robotics Announces Closing of $40.0 Million Private Placement Priced At-the-Market

2021-02-26T17:41:59Z

MARLBOROUGH, Mass. and BERLIN and YOKNEAM ILIT, Israel, Feb. 26, 2021 (GLOBE NEWSWIRE) -- ?ReWalk Robotics Ltd. (Nasdaq: RWLK) (��ReWalk�� or the ��Company��) today announced the closing of its previously announced private placement of 10,921,502 ordinary shares and warrants to purchase up to 5,460,751 ordinary shares, at a purchase price of $3.6625 per share and associated warrant, that was priced ��at-the-market�� under Nasdaq rules and resulted in gross proceeds of approximately $40.0 million before the deduction of placement agent fees and expenses and estimated offering expenses payable by the Company. The warrants have a term of five and one-half years, are exercisable immediately and have an exercise price of $3.60 per ordinary share.

Kaspersky shares state of stalkerware in 2020

2021-02-26T14:02:00Z

Woburn, MA, Feb. 26, 2021 (GLOBE NEWSWIRE) -- Today Kaspersky released ��The State of Stalkerware 2020�� report, which captures the incidence of the secret surveillance software often used in cases of domestic violence. The report found that 53,870 mobile users were affected globally by stalkerware in 2020. The figure is a slight drop from the year before, when 67,500 mobile users were affected, but the yearly curve began to rise again in the second half of 2020, after some lockdown measures were lifted.

Innovation Pharma Provides Study Details for Ongoing Phase 2 Clinical Trial of Brilacidin in Hospitalized COVID-19 Patients

2021-02-26T14:00:00Z

WAKEFIELD, Mass., Feb. 26, 2021 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (��the Company��), a clinical stage biopharmaceutical company, today provides additional study details for its ongoing Phase 2 clinical trial assessing Brilacidin as a novel therapeutic in hospitalized patients with COVID-19. Patients are being treated, with recruitment and enrollment progressing at trial sites.

Albireo Spotlights Global Patient Communities on Rare Disease Day

2021-02-26T13:30:00Z

�C Calls to unite global communities affected by rare diseases �C

uniQure to Participate in Multiple Upcoming Industry Conferences in March

2021-02-26T12:05:00Z

LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Feb. 26, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced its participation in the following upcoming virtual investor and scientific conferences:

Fulcrum Therapeutics to Host Fourth Quarter and Full Year 2020 Financial Results Conference Call and Webcast on Thursday, March 4, 2021 at 8:00 a.m. ET

2021-02-26T12:00:00Z

CAMBRIDGE, Mass., Feb. 26, 2021 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.?(Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that its fourth quarter and full year 2020 financial results will be released on Thursday, March 4, 2021 before the U.S. financial markets open. Management will host a conference call and webcast at 8:00 a.m. ET to discuss the results and provide an update on recent corporate developments.

Fulcrum Therapeutics Recognizes Rare Disease Day 2021

2021-02-26T12:00:00Z

Theme of global unity highlights critical role of building communities of support for patients and families affected by rare diseases around the world

Theme of global unity highlights critical role of building communities of support for patients and families affected by rare diseases around the world

Agios Recognizes 14th Annual Rare Disease Day and Raises Awareness of Unmet Needs in Rare Hemolytic Anemias

2021-02-26T12:00:00Z

�C In Partnership with the Sickle Cell Community Consortium, Agios Works to Address Educational Resource Gaps Caused by COVID-19 for Students with Sickle Cell Disease �C

DraftKings Reports Fourth Quarter and Full-Year 2020 Results and Raises 2021 Revenue Guidance

2021-02-26T12:00:00Z

Reports Fourth Quarter Revenue of $322 million; Increases 2021 Revenue Guidance to $900 million to $1 billion

Reports Fourth Quarter Revenue of $322 million; Increases 2021 Revenue Guidance to $900 million to $1 billion

Mersana Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update

2021-02-26T11:00:00Z

- UPLIFT, a single-arm registration strategy evaluating upifitamab rilsodotin (UpRi) in platinum-resistant ovarian cancer, on track to begin in Q1 2021

SHAREHOLDER ALERT: Tricida, Inc. Sued for Violations of the Federal Securities Laws; Investors Should Contact Block & Leviton LLP

2021-02-25T22:34:36Z

BOSTON, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Nationally-recognized securities law firm Block & Leviton LLP (www.blockleviton.com) announces that a lawsuit for violation of the federal securities laws has been filed against Tricida, Inc. (NASDAQ: TCDA) and certain of its executives.

LeMaitre Q4 2020 Financial Results

2021-02-25T21:15:00Z

BURLINGTON, Mass., Feb. 25, 2021 (GLOBE NEWSWIRE) -- LeMaitre (Nasdaq:LMAT), a provider of vascular devices, implants and services, today reported Q4 2020 results and announced an $0.11/share quarterly dividend.

Vicor Corporation Reports Results for the Fourth Quarter and Year Ended December 31, 2020

2021-02-25T21:05:00Z

ANDOVER, Mass., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Vicor Corporation (NASDAQ: VICR) today reported financial results for the fourth quarter ended December 31, 2020.??

Ziopharm Oncology Provides Leadership and Corporate Updates; Reports Fourth Quarter and Full Year 2020 Financial Results

2021-02-25T21:05:00Z

Heidi Hagen Appointed Interim Chief Executive Officer Replacing Dr. Laurence Cooper; Search for Permanent CEO Initiated

Translate Bio Announces Fourth Quarter and Full Year 2020 Financial Results and Highlights Recent Progress

2021-02-25T21:05:00Z

-- Additional interim data expected in early Q2 from Phase 1/2 clinical trial of MRT5005 for the treatment of cystic fibrosis (CF) --

-- Two infectious disease mRNA vaccine programs expected to enter clinic in 2021: COVID-19 in Q1 and influenza in mid-2021, in collaboration with partner Sanofi Pasteur --

Voyager Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Corporate Updates

2021-02-25T21:01:00Z

CAMBRIDGE, Mass., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases, today reported its fourth quarter and full year 2020 financial results and provided corporate updates.

Collegium Reports Record Full-Year 2020 Revenue of $310.0 Million

2021-02-25T21:01:00Z

�C 2020 First Full-Year of Profitability, Driven by Xtampza^? ER Revenue Growth and the Nucynta^? Acquisition �C